{
  "id": 16696189,
  "title": "Charles River director James Foster sells $8.4 million in shares",
  "url": "https://urgent.news/2026/10/27/charles-river-director-james-foster-sells-8-4-million-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-27T02:31:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/charles-river-director-james-foster-sells-84-million-in-shares-93CH-4974087"
  },
  "original_language": "en",
  "account": "Charles River Laboratories International, Inc. (CRL) saw significant stock activity on October 22, 2026. CEO James C. Foster bought 24,042 shares at $244.41 each, investing $5.88 million. Simultaneously, Foster sold the same number of shares at $350.00 per share, generating $8.41 million. This trade was executed under a pre-approved Rule 10b5-1 plan since March 6, 2026. Shares were trading close to their 52-week high of $357.77, currently priced at $357.27. Analysts label CRL as overvalued, as per InvestingPro's assessment. In the last six months, CRL shares have climbed over 108%. CRL's upcoming earnings are set for November 4. Following Foster's transactions, he directly owns 31,596 shares. Indirectly, he holds shares via trusts: 5,423 shares through a 2024 GRAT, 10,780 shares through a 2025 GRAT, 20,000 shares via a 2026 GRAT, 10,000 shares held by his spouse, and 155,611 shares in another trust. Analysts have recently updated their outlook on CRL. UBS gave a buy rating, Jefferies maintained buy and raised price target to $340, TD Cowen increased target to $325, and Mizuho adjusted to $295.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}